Paul Howard is a Partner and founder of Mediphase Venture Partners. Mr. Howard concentrates his efforts on the Life Sciences companies in the portfolios. He has invested in over 25 private companies that include Tularik, Exelixis, CV Therapeutics, Cubist, Rosetta Inpharmatics, Dyax and LJL Biosytems. Mr. Howard serves on the Board of Directors of Supplemental Health Care and Serenex.
Prior to founding Mediphase Venture Partners, Mr. Howard was a Senior Vice President at Hambrecht & Quist Capital Management in Boston from 1992-1999, where he was responsible for managing the fund’s biotechnology investments. From 1983-1990 Mr. Howard was a Senior Technical Sales Executive for the Miles Biotechnology Division of Bayer A.G.
